Esperion Therapeutics (ESPR) Misses Q1 EPS by 8c
Tweet
Share
E-mailGet Alerts ESPR Hot Sheet
Join SI Premium – FREE
Esperion Therapeutics (NASDAQ: ESPR) reported Q1 EPS of ($0.56), $0.08 worse than the analyst estimate of ($0.48).
For earnings history and earnings-related data on Esperion Therapeutics (ESPR) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman lowers Mattel rating to Sell on macro and execution risks; shares dip
- Stellantis stock slips as JPMorgan downgrades on delayed payoff from cost cuts
- Steel Partners offers $16.75 per share to acquire InMode
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
